JP2009502965A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502965A5 JP2009502965A5 JP2008524245A JP2008524245A JP2009502965A5 JP 2009502965 A5 JP2009502965 A5 JP 2009502965A5 JP 2008524245 A JP2008524245 A JP 2008524245A JP 2008524245 A JP2008524245 A JP 2008524245A JP 2009502965 A5 JP2009502965 A5 JP 2009502965A5
- Authority
- JP
- Japan
- Prior art keywords
- shows
- mupirocin
- nisin
- treatment
- aureus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010053775 Nisin Proteins 0.000 description 9
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 9
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 9
- 239000004309 nisin Substances 0.000 description 9
- 235000010297 nisin Nutrition 0.000 description 9
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 8
- 229960003128 mupirocin Drugs 0.000 description 8
- 229930187697 mupirocin Natural products 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 108010001478 Bacitracin Proteins 0.000 description 4
- 229960003071 bacitracin Drugs 0.000 description 4
- 229930184125 bacitracin Natural products 0.000 description 4
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010041925 Staphylococcal infections Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108090000988 Lysostaphin Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70301005P | 2005-07-28 | 2005-07-28 | |
| US60/703,010 | 2005-07-28 | ||
| US72519305P | 2005-10-11 | 2005-10-11 | |
| US60/725,193 | 2005-10-11 | ||
| US77903406P | 2006-03-03 | 2006-03-03 | |
| US60/779,034 | 2006-03-03 | ||
| PCT/US2006/029672 WO2007014372A2 (en) | 2005-07-28 | 2006-07-28 | Compositions and methods for treating bacteria |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009502965A JP2009502965A (ja) | 2009-01-29 |
| JP2009502965A5 true JP2009502965A5 (https=) | 2012-07-26 |
| JP5619352B2 JP5619352B2 (ja) | 2014-11-05 |
Family
ID=37684026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008524245A Expired - Fee Related JP5619352B2 (ja) | 2005-07-28 | 2006-07-28 | 細菌を処置するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7517852B2 (https=) |
| EP (1) | EP1940437B1 (https=) |
| JP (1) | JP5619352B2 (https=) |
| CA (1) | CA2617133C (https=) |
| ES (1) | ES2436614T3 (https=) |
| WO (1) | WO2007014372A2 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517852B2 (en) * | 2005-07-28 | 2009-04-14 | Biosynexus Incorporated | Compositions and methods for treating bacteria |
| WO2007044745A1 (en) * | 2005-10-11 | 2007-04-19 | Biosynexus Incorporated | Lantibiotic and mupirocin compositions for treating bacterial infections |
| US9115358B2 (en) | 2006-08-11 | 2015-08-25 | President And Fellows Of Harvard College | Moenomycin biosynthesis-related compositions and methods of use thereof |
| US9427468B2 (en) * | 2007-08-22 | 2016-08-30 | Trustees Of Dartmouth College | Compositions and methods for diagnosing and treating community-acquired methicillin-resistant Staphylococcus aureus |
| EP2205074A4 (en) * | 2007-10-04 | 2013-07-31 | Harvard College | MOENOMYCIN ANALOGUE, SYNTHESIS PROCESS AND USE |
| US20100008993A1 (en) * | 2008-07-14 | 2010-01-14 | Proksch Joel W | Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs |
| JP5374260B2 (ja) * | 2009-07-10 | 2013-12-25 | 静岡商工会議所 | 農業用資材 |
| WO2012033634A2 (en) * | 2010-09-09 | 2012-03-15 | Mary Kay Inc. | Topical skin care formulations comprising plant extracts |
| EP2648676A4 (en) | 2010-12-06 | 2016-05-04 | Follica Inc | METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH |
| WO2012125941A1 (en) * | 2011-03-17 | 2012-09-20 | Follica, Inc. | Lithium treatment for microbial infections |
| US9918479B2 (en) | 2012-02-28 | 2018-03-20 | Marrone Bio Innovations, Inc. | Control of phytopathogenic microorganisms with Pseudomonas sp. and substances and compositions derived therefrom |
| WO2013152277A2 (en) | 2012-04-06 | 2013-10-10 | President And Fellows Of Harvard College | Moenomycin analogs, methods of synthesis, and uses thereof |
| EP2850090B1 (en) | 2012-04-06 | 2018-10-03 | President and Fellows of Harvard College | Chemoenzymatic methods for synthesizing moenomycin analogs |
| EP2850091A1 (en) | 2012-04-06 | 2015-03-25 | President and Fellows of Harvard College | Methods and compounds for identifying glycosyltransferase inhibitors |
| EP3194609B1 (en) | 2014-09-16 | 2019-08-28 | President and Fellows of Harvard College | Engineered water nanostructures (ewns) and uses thereof |
| US10617703B2 (en) * | 2014-12-10 | 2020-04-14 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US11793783B2 (en) | 2015-08-05 | 2023-10-24 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US12502370B2 (en) * | 2019-04-11 | 2025-12-23 | Cmpd Licensing, Llc | Wound treatments and compositions |
| US11446236B2 (en) | 2015-08-05 | 2022-09-20 | Cmpd Licensing, Llc | Topical antimicrobial compositions and methods of formulating the same |
| EP3331496B1 (en) * | 2015-08-05 | 2021-01-27 | The University of Rochester | Antimicrobial compositions comprising mupirocin and neomycin |
| US11684567B2 (en) | 2015-08-05 | 2023-06-27 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| AU2017240069B2 (en) | 2016-03-31 | 2024-03-07 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
| WO2017173240A1 (en) | 2016-03-31 | 2017-10-05 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
| EP3435765A1 (en) | 2016-03-31 | 2019-02-06 | Gojo Industries, Inc. | Antimicrobial peptide stimulating sanitizing composition |
| EP3544575A1 (en) | 2016-11-23 | 2019-10-02 | GOJO Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
| EP3701367B1 (en) | 2017-10-27 | 2022-06-01 | Canon Production Printing Holding B.V. | Controller for a multi-roll printer, printing system and method for controlling a multi-roll printer |
| WO2020185562A1 (en) * | 2019-03-08 | 2020-09-17 | Fraunhofer Usa, Inc. | Novel antimicrobial lantibiotic peptide and uses thereof |
| US12156875B2 (en) | 2019-04-11 | 2024-12-03 | Cmpd Licensing, Llc | Wound treatments and compositions |
| US12433853B2 (en) | 2019-08-26 | 2025-10-07 | Kent State University | Rationally designed lawsone derivatives as antimicrobials against multidrug-resistant Staphylococcus aureus |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5135910A (en) * | 1988-06-22 | 1992-08-04 | The Public Health Research Institute Of The City Of New York | Nisin compositions for use as enhanced, broad range bactericides |
| US5260271A (en) | 1988-06-22 | 1993-11-09 | Applied Microbiology, Inc. | Nisin compositions for use as enhanced broad range bactericides |
| DK0579730T3 (da) * | 1991-04-11 | 2003-03-31 | Stichting Nl I Voor Zuivelonde | Nisin A-lignende lantibiotika, mælkesyrebakterie der producerer sådanne lantibiotika, fremgangsmåde til konstruktion af sådanne mælkesyrebakterier og fremgangsmåde til konservering . . . |
| ES2157985T3 (es) | 1993-08-20 | 2001-09-01 | Novartis Ag | Metodo para la prevencion y el tratamiento de la mastitis bovina. |
| GB9423404D0 (en) * | 1994-11-19 | 1995-01-11 | Biotech & Biolog Scien Res | Production of nisin |
| CN1138560C (zh) * | 1995-06-23 | 2004-02-18 | Ambi股份有限公司 | 控制对抗生素耐药的革兰氏阳性细菌的方法和治疗感染的方法 |
| US5928146A (en) * | 1996-03-15 | 1999-07-27 | Hitachi Medical Corporation | Inspection apparatus using nuclear magnetic resonance |
| US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
| US6180604B1 (en) | 1996-08-21 | 2001-01-30 | Micrologix Biotech Inc. | Compositions and methods for treating infections using analogues of indolicidin |
| CO4910145A1 (es) * | 1996-10-01 | 2000-04-24 | Smithkline Beecham Corp | Uso |
| IL123143A (en) * | 1998-02-02 | 2001-08-26 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing mupirocin |
| IL137363A (en) * | 2000-07-18 | 2005-12-18 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing mupirocin |
| ES2532906T5 (es) * | 2002-10-25 | 2022-03-23 | Foamix Pharmaceuticals Ltd | Espuma cosmética y farmacéutica |
| AU2003296937A1 (en) * | 2002-12-10 | 2004-06-30 | Biosynexus Incorporated | Topical anti-infective formulations |
| US7517852B2 (en) * | 2005-07-28 | 2009-04-14 | Biosynexus Incorporated | Compositions and methods for treating bacteria |
| WO2007044745A1 (en) * | 2005-10-11 | 2007-04-19 | Biosynexus Incorporated | Lantibiotic and mupirocin compositions for treating bacterial infections |
-
2006
- 2006-07-28 US US11/494,887 patent/US7517852B2/en not_active Expired - Fee Related
- 2006-07-28 EP EP06813251.3A patent/EP1940437B1/en active Active
- 2006-07-28 CA CA2617133A patent/CA2617133C/en not_active Expired - Fee Related
- 2006-07-28 JP JP2008524245A patent/JP5619352B2/ja not_active Expired - Fee Related
- 2006-07-28 WO PCT/US2006/029672 patent/WO2007014372A2/en not_active Ceased
- 2006-07-28 ES ES06813251.3T patent/ES2436614T3/es active Active
-
2009
- 2009-04-13 US US12/422,813 patent/US8697639B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009502965A5 (https=) | ||
| Yadav et al. | Eugenol: a phyto-compound effective against methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical strain biofilms | |
| El-Feky et al. | Effect of ciprofloxacin and N-acetylcysteine on bacterial adherence and biofilm formation on ureteral stent surfaces | |
| Marcinkiewicz et al. | Antibiotic resistance: a" dark side" of biofilm‑associated chronic infections | |
| Yadav et al. | In vitro multi-species biofilms of methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa and their host interaction during in vivo colonization of an otitis media rat model | |
| Campeau et al. | Antibiofilm activity of Manuka honey in combination with antibiotics | |
| Tran et al. | A study on the ability of quaternary ammonium groups attached to a polyurethane foam wound dressing to inhibit bacterial attachment and biofilm formation | |
| NZ593831A (en) | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces | |
| WO2005072281A3 (en) | Methods for coating and impregnating medical devices with antiseptic compositions | |
| WO2008085578A3 (en) | Anti-microbial compositions and devices and methods of using the same | |
| WO2009108406A3 (en) | Engineered bacteriophages as adjuvants for antimicrobial agents and compositions and methods of use thereof | |
| RU2018107249A (ru) | Применение лизина для восстановления/увеличения антибактериальной активности антибиотиков в присутствии легочного сурфактанта, который ингибирует указанные антибиотики | |
| Meije et al. | Daptomycin is effective as antibiotic-lock therapy in a model of Staphylococcus aureus catheter-related infection | |
| WO2010091124A3 (en) | Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications | |
| WO2010036876A3 (en) | Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota | |
| MX2021005136A (es) | Composiciones y métodos para el tratamiento de biopelículas sin inducir resistencia a los antimicrobianos. | |
| BRPI1010948A2 (pt) | Composição compreendendo pelo menos trans- cinamaldeído e a respectiva utilização no tratamento das infecções bacterianas, mais particularmente no tratamento das doenças nosocomiais. | |
| Renner et al. | Persistence of bacteria like Pseudomonas aeruginosa in non-healing venous ulcers | |
| Drapeau et al. | Rifampicin combined regimens for Gram-negative infections: data from the literature | |
| WO2008103751A3 (en) | Antimicrobial and anti-inflammatory therapies and compositions | |
| JP2018500387A5 (https=) | ||
| WO2016105510A3 (en) | Methods and compositions for growth, storage, and use of bacterial preparations for wound and surface treatments | |
| PH12021553086A1 (en) | Medicament and use thereof for treating bacterial infections involving biofilm | |
| JP2013539776A5 (https=) | ||
| JP2008518699A5 (https=) |